世界の遺伝性アミロイドーシス治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Hereditary Amyloidosis Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4307 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、遺伝性アミロイドーシス治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、外科治療）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・遺伝性アミロイドーシス治療の市場動向 ・企業の競争状況、市場シェア ・遺伝性アミロイドーシス治療の種類別市場規模と予測2016-2027（薬物治療、外科治療） ・遺伝性アミロイドーシス治療の用途別市場規模と予測2016-2027（病院、診療所、その他） ・遺伝性アミロイドーシス治療の北米市場規模2016-2027（アメリカ、カナダ） ・遺伝性アミロイドーシス治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・遺伝性アミロイドーシス治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・遺伝性アミロイドーシス治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・遺伝性アミロイドーシス治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Baxter、Johnson & Johnson、Alnylam Pharmaceuticals、Pfizer、Prothena、GlaxoSmithKline、Ionis Pharmaceuticals、BridgeBio Pharma、SOM Innovation Biotech） ・結論

Hereditary Amyloidosis is one of the amyloidosis disease that is caused by inherited genetic mutation.

Market Analysis and Insights: Global Hereditary Amyloidosis Treatment Market
The global Hereditary Amyloidosis Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hereditary Amyloidosis Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hereditary Amyloidosis Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hereditary Amyloidosis Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hereditary Amyloidosis Treatment market.

Global Hereditary Amyloidosis Treatment Scope and Market Size
Hereditary Amyloidosis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hereditary Amyloidosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Drug Treatment
Surgical Treatment

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Baxter
Johnson & Johnson
Alnylam Pharmaceuticals
Pfizer
Prothena
GlaxoSmithKline
Ionis Pharmaceuticals
BridgeBio Pharma
SOM Innovation Biotech

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hereditary Amyloidosis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drug Treatment
1.2.3 Surgical Treatment
1.3 Market by Application
1.3.1 Global Hereditary Amyloidosis Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Hereditary Amyloidosis Treatment Market Perspective (2016-2027)
2.2 Hereditary Amyloidosis Treatment Growth Trends by Regions
2.2.1 Hereditary Amyloidosis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hereditary Amyloidosis Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Hereditary Amyloidosis Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Hereditary Amyloidosis Treatment Industry Dynamic
2.3.1 Hereditary Amyloidosis Treatment Market Trends
2.3.2 Hereditary Amyloidosis Treatment Market Drivers
2.3.3 Hereditary Amyloidosis Treatment Market Challenges
2.3.4 Hereditary Amyloidosis Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Hereditary Amyloidosis Treatment Players by Revenue
3.1.1 Global Top Hereditary Amyloidosis Treatment Players by Revenue (2016-2021)
3.1.2 Global Hereditary Amyloidosis Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Hereditary Amyloidosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hereditary Amyloidosis Treatment Revenue
3.4 Global Hereditary Amyloidosis Treatment Market Concentration Ratio
3.4.1 Global Hereditary Amyloidosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hereditary Amyloidosis Treatment Revenue in 2020
3.5 Hereditary Amyloidosis Treatment Key Players Head office and Area Served
3.6 Key Players Hereditary Amyloidosis Treatment Product Solution and Service
3.7 Date of Enter into Hereditary Amyloidosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Hereditary Amyloidosis Treatment Breakdown Data by Type
4.1 Global Hereditary Amyloidosis Treatment Historic Market Size by Type (2016-2021)
4.2 Global Hereditary Amyloidosis Treatment Forecasted Market Size by Type (2022-2027)

5 Hereditary Amyloidosis Treatment Breakdown Data by Application
5.1 Global Hereditary Amyloidosis Treatment Historic Market Size by Application (2016-2021)
5.2 Global Hereditary Amyloidosis Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Hereditary Amyloidosis Treatment Market Size (2016-2027)
6.2 North America Hereditary Amyloidosis Treatment Market Size by Type
6.2.1 North America Hereditary Amyloidosis Treatment Market Size by Type (2016-2021)
6.2.2 North America Hereditary Amyloidosis Treatment Market Size by Type (2022-2027)
6.2.3 North America Hereditary Amyloidosis Treatment Market Size by Type (2016-2027)
6.3 North America Hereditary Amyloidosis Treatment Market Size by Application
6.3.1 North America Hereditary Amyloidosis Treatment Market Size by Application (2016-2021)
6.3.2 North America Hereditary Amyloidosis Treatment Market Size by Application (2022-2027)
6.3.3 North America Hereditary Amyloidosis Treatment Market Size by Application (2016-2027)
6.4 North America Hereditary Amyloidosis Treatment Market Size by Country
6.4.1 North America Hereditary Amyloidosis Treatment Market Size by Country (2016-2021)
6.4.2 North America Hereditary Amyloidosis Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Hereditary Amyloidosis Treatment Market Size (2016-2027)
7.2 Europe Hereditary Amyloidosis Treatment Market Size by Type
7.2.1 Europe Hereditary Amyloidosis Treatment Market Size by Type (2016-2021)
7.2.2 Europe Hereditary Amyloidosis Treatment Market Size by Type (2022-2027)
7.2.3 Europe Hereditary Amyloidosis Treatment Market Size by Type (2016-2027)
7.3 Europe Hereditary Amyloidosis Treatment Market Size by Application
7.3.1 Europe Hereditary Amyloidosis Treatment Market Size by Application (2016-2021)
7.3.2 Europe Hereditary Amyloidosis Treatment Market Size by Application (2022-2027)
7.3.3 Europe Hereditary Amyloidosis Treatment Market Size by Application (2016-2027)
7.4 Europe Hereditary Amyloidosis Treatment Market Size by Country
7.4.1 Europe Hereditary Amyloidosis Treatment Market Size by Country (2016-2021)
7.4.2 Europe Hereditary Amyloidosis Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Hereditary Amyloidosis Treatment Market Size (2016-2027)
8.2 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Type
8.2.1 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Application
8.3.1 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Region
8.4.1 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Hereditary Amyloidosis Treatment Market Size (2016-2027)
9.2 Latin America Hereditary Amyloidosis Treatment Market Size by Type
9.2.1 Latin America Hereditary Amyloidosis Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Hereditary Amyloidosis Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Hereditary Amyloidosis Treatment Market Size by Type (2016-2027)
9.3 Latin America Hereditary Amyloidosis Treatment Market Size by Application
9.3.1 Latin America Hereditary Amyloidosis Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Hereditary Amyloidosis Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Hereditary Amyloidosis Treatment Market Size by Application (2016-2027)
9.4 Latin America Hereditary Amyloidosis Treatment Market Size by Country
9.4.1 Latin America Hereditary Amyloidosis Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Hereditary Amyloidosis Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Hereditary Amyloidosis Treatment Market Size (2016-2027)
10.2 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Type
10.2.1 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Application
10.3.1 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Country
10.4.1 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Baxter
11.1.1 Baxter Company Details
11.1.2 Baxter Business Overview
11.1.3 Baxter Hereditary Amyloidosis Treatment Introduction
11.1.4 Baxter Revenue in Hereditary Amyloidosis Treatment Business (2016-2021)
11.1.5 Baxter Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Hereditary Amyloidosis Treatment Introduction
11.2.4 Johnson & Johnson Revenue in Hereditary Amyloidosis Treatment Business (2016-2021)
11.2.5 Johnson & Johnson Recent Development
11.3 Alnylam Pharmaceuticals
11.3.1 Alnylam Pharmaceuticals Company Details
11.3.2 Alnylam Pharmaceuticals Business Overview
11.3.3 Alnylam Pharmaceuticals Hereditary Amyloidosis Treatment Introduction
11.3.4 Alnylam Pharmaceuticals Revenue in Hereditary Amyloidosis Treatment Business (2016-2021)
11.3.5 Alnylam Pharmaceuticals Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Hereditary Amyloidosis Treatment Introduction
11.4.4 Pfizer Revenue in Hereditary Amyloidosis Treatment Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Prothena
11.5.1 Prothena Company Details
11.5.2 Prothena Business Overview
11.5.3 Prothena Hereditary Amyloidosis Treatment Introduction
11.5.4 Prothena Revenue in Hereditary Amyloidosis Treatment Business (2016-2021)
11.5.5 Prothena Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Hereditary Amyloidosis Treatment Introduction
11.6.4 GlaxoSmithKline Revenue in Hereditary Amyloidosis Treatment Business (2016-2021)
11.6.5 GlaxoSmithKline Recent Development
11.7 Ionis Pharmaceuticals
11.7.1 Ionis Pharmaceuticals Company Details
11.7.2 Ionis Pharmaceuticals Business Overview
11.7.3 Ionis Pharmaceuticals Hereditary Amyloidosis Treatment Introduction
11.7.4 Ionis Pharmaceuticals Revenue in Hereditary Amyloidosis Treatment Business (2016-2021)
11.7.5 Ionis Pharmaceuticals Recent Development
11.8 BridgeBio Pharma
11.8.1 BridgeBio Pharma Company Details
11.8.2 BridgeBio Pharma Business Overview
11.8.3 BridgeBio Pharma Hereditary Amyloidosis Treatment Introduction
11.8.4 BridgeBio Pharma Revenue in Hereditary Amyloidosis Treatment Business (2016-2021)
11.8.5 BridgeBio Pharma Recent Development
11.9 SOM Innovation Biotech
11.9.1 SOM Innovation Biotech Company Details
11.9.2 SOM Innovation Biotech Business Overview
11.9.3 SOM Innovation Biotech Hereditary Amyloidosis Treatment Introduction
11.9.4 SOM Innovation Biotech Revenue in Hereditary Amyloidosis Treatment Business (2016-2021)
11.9.5 SOM Innovation Biotech Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Hereditary Amyloidosis Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drug Treatment
Table 3. Key Players of Surgical Treatment
Table 4. Global Hereditary Amyloidosis Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Hereditary Amyloidosis Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Hereditary Amyloidosis Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Hereditary Amyloidosis Treatment Market Share by Regions (2016-2021)
Table 8. Global Hereditary Amyloidosis Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Hereditary Amyloidosis Treatment Market Share by Regions (2022-2027)
Table 10. Hereditary Amyloidosis Treatment Market Trends
Table 11. Hereditary Amyloidosis Treatment Market Drivers
Table 12. Hereditary Amyloidosis Treatment Market Challenges
Table 13. Hereditary Amyloidosis Treatment Market Restraints
Table 14. Global Hereditary Amyloidosis Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Hereditary Amyloidosis Treatment Market Share by Players (2016-2021)
Table 16. Global Top Hereditary Amyloidosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hereditary Amyloidosis Treatment as of 2020)
Table 17. Ranking of Global Top Hereditary Amyloidosis Treatment Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Hereditary Amyloidosis Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Hereditary Amyloidosis Treatment Product Solution and Service
Table 21. Date of Enter into Hereditary Amyloidosis Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Hereditary Amyloidosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Hereditary Amyloidosis Treatment Revenue Market Share by Type (2016-2021)
Table 25. Global Hereditary Amyloidosis Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Hereditary Amyloidosis Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Hereditary Amyloidosis Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Hereditary Amyloidosis Treatment Revenue Market Share by Application (2016-2021)
Table 29. Global Hereditary Amyloidosis Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Hereditary Amyloidosis Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Hereditary Amyloidosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Hereditary Amyloidosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Hereditary Amyloidosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Hereditary Amyloidosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Hereditary Amyloidosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Hereditary Amyloidosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Hereditary Amyloidosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Hereditary Amyloidosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Hereditary Amyloidosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Hereditary Amyloidosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Hereditary Amyloidosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Hereditary Amyloidosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Hereditary Amyloidosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Hereditary Amyloidosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Hereditary Amyloidosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Hereditary Amyloidosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Hereditary Amyloidosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Hereditary Amyloidosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 61. Baxter Company Details
Table 62. Baxter Business Overview
Table 63. Baxter Hereditary Amyloidosis Treatment Product
Table 64. Baxter Revenue in Hereditary Amyloidosis Treatment Business (2016-2021) & (US$ Million)
Table 65. Baxter Recent Development
Table 66. Johnson & Johnson Company Details
Table 67. Johnson & Johnson Business Overview
Table 68. Johnson & Johnson Hereditary Amyloidosis Treatment Product
Table 69. Johnson & Johnson Revenue in Hereditary Amyloidosis Treatment Business (2016-2021) & (US$ Million)
Table 70. Johnson & Johnson Recent Development
Table 71. Alnylam Pharmaceuticals Company Details
Table 72. Alnylam Pharmaceuticals Business Overview
Table 73. Alnylam Pharmaceuticals Hereditary Amyloidosis Treatment Product
Table 74. Alnylam Pharmaceuticals Revenue in Hereditary Amyloidosis Treatment Business (2016-2021) & (US$ Million)
Table 75. Alnylam Pharmaceuticals Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Hereditary Amyloidosis Treatment Product
Table 79. Pfizer Revenue in Hereditary Amyloidosis Treatment Business (2016-2021) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Prothena Company Details
Table 82. Prothena Business Overview
Table 83. Prothena Hereditary Amyloidosis Treatment Product
Table 84. Prothena Revenue in Hereditary Amyloidosis Treatment Business (2016-2021) & (US$ Million)
Table 85. Prothena Recent Development
Table 86. GlaxoSmithKline Company Details
Table 87. GlaxoSmithKline Business Overview
Table 88. GlaxoSmithKline Hereditary Amyloidosis Treatment Product
Table 89. GlaxoSmithKline Revenue in Hereditary Amyloidosis Treatment Business (2016-2021) & (US$ Million)
Table 90. GlaxoSmithKline Recent Development
Table 91. Ionis Pharmaceuticals Company Details
Table 92. Ionis Pharmaceuticals Business Overview
Table 93. Ionis Pharmaceuticals Hereditary Amyloidosis Treatment Product
Table 94. Ionis Pharmaceuticals Revenue in Hereditary Amyloidosis Treatment Business (2016-2021) & (US$ Million)
Table 95. Ionis Pharmaceuticals Recent Development
Table 96. BridgeBio Pharma Company Details
Table 97. BridgeBio Pharma Business Overview
Table 98. BridgeBio Pharma Revenue in Hereditary Amyloidosis Treatment Business (2016-2021) & (US$ Million)
Table 99. BridgeBio Pharma Recent Development
Table 100. SOM Innovation Biotech Company Details
Table 101. SOM Innovation Biotech Business Overview
Table 102. SOM Innovation Biotech Hereditary Amyloidosis Treatment Product
Table 103. SOM Innovation Biotech Revenue in Hereditary Amyloidosis Treatment Business (2016-2021) & (US$ Million)
Table 104. SOM Innovation Biotech Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hereditary Amyloidosis Treatment Market Share by Type: 2020 VS 2027
Figure 2. Drug Treatment Features
Figure 3. Surgical Treatment Features
Figure 4. Global Hereditary Amyloidosis Treatment Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Others Case Studies
Figure 8. Hereditary Amyloidosis Treatment Report Years Considered
Figure 9. Global Hereditary Amyloidosis Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Hereditary Amyloidosis Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Hereditary Amyloidosis Treatment Market Share by Regions: 2020 VS 2027
Figure 12. Global Hereditary Amyloidosis Treatment Market Share by Regions (2022-2027)
Figure 13. Global Hereditary Amyloidosis Treatment Market Share by Players in 2020
Figure 14. Global Top Hereditary Amyloidosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hereditary Amyloidosis Treatment as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Hereditary Amyloidosis Treatment Revenue in 2020
Figure 16. Global Hereditary Amyloidosis Treatment Revenue Market Share by Type (2016-2021)
Figure 17. Global Hereditary Amyloidosis Treatment Revenue Market Share by Type (2022-2027)
Figure 18. North America Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Hereditary Amyloidosis Treatment Market Share by Type (2016-2027)
Figure 20. North America Hereditary Amyloidosis Treatment Market Share by Application (2016-2027)
Figure 21. North America Hereditary Amyloidosis Treatment Market Share by Country (2016-2027)
Figure 22. United States Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Hereditary Amyloidosis Treatment Market Share by Type (2016-2027)
Figure 26. Europe Hereditary Amyloidosis Treatment Market Share by Application (2016-2027)
Figure 27. Europe Hereditary Amyloidosis Treatment Market Share by Country (2016-2027)
Figure 28. Germany Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Hereditary Amyloidosis Treatment Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Hereditary Amyloidosis Treatment Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Hereditary Amyloidosis Treatment Market Share by Region (2016-2027)
Figure 38. China Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Hereditary Amyloidosis Treatment Market Share by Type (2016-2027)
Figure 46. Latin America Hereditary Amyloidosis Treatment Market Share by Application (2016-2027)
Figure 47. Latin America Hereditary Amyloidosis Treatment Market Share by Country (2016-2027)
Figure 48. Mexico Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Hereditary Amyloidosis Treatment Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Hereditary Amyloidosis Treatment Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Hereditary Amyloidosis Treatment Market Share by Country (2016-2027)
Figure 54. Turkey Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Hereditary Amyloidosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Baxter Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2016-2021)
Figure 58. Johnson & Johnson Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2016-2021)
Figure 59. Alnylam Pharmaceuticals Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2016-2021)
Figure 61. Prothena Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2016-2021)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2016-2021)
Figure 63. Ionis Pharmaceuticals Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2016-2021)
Figure 64. BridgeBio Pharma Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2016-2021)
Figure 65. SOM Innovation Biotech Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---